Immedica's Acquisition of Marinus Pharmaceuticals: A Strategic Move for Global Rare Disease Expansion

Immedica Pharma AB (Immedica), a leading global rare disease company, has announced its acquisition of Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) through a cash tender offer of $0.55 per share. This strategic move complements Immedica's global rare disease business and accelerates its growth into the North American market. The acquisition is expected to close in the first quarter of 2025, subject to customary conditions and regulatory approvals.



The acquisition adds global rights to ZTALMY® (ganaxalone) oral suspension, a commercial-stage rare neurology medicine approved by the U.S. Food and Drug Administration (FDA), the European Commission (EC), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and the National Medicines Product Administration (NMPA) in China. ZTALMY is approved for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years of age and older.

Accelerating Immedica's growth into the North American market, the acquisition provides an immediate revenue-generating rare disease product and an experienced commercial team upon closing of the transaction. This strategic move is expected to accelerate Immedica's revenue growth, adding a commercial-stage asset in the United States with the potential for further expansion globally.

Immedica's Chief Executive Officer, Anders Edvell, M.D. Ph.D., stated, "The acquisition of Marinus represents a transformative step in Immedica’s journey to further strengthen our position as a leading rare disease company. By adding ZTALMY to our portfolio, we significantly strengthen our capabilities and expand our presence in the United States, marking a new chapter in our mission to deliver impactful therapies for underserved patient populations."

Marinus Pharmaceuticals' Chief Executive Officer, Scott Braunstein, M.D., added, "With a shared commitment to improving the lives of rare disease patients, this acquisition is expected to enable ZTALMY to make an even greater impact on patients, while providing meaningful value for Marinus’ stockholders."

The acquisition is expected to accelerate Immedica's revenue growth, adding a commercial-stage asset in the United States with the potential for further expansion globally. The addition of ZTALMY to Immedica's portfolio will significantly strengthen its capabilities and expand its presence in the United States, marking a new chapter in its mission to deliver impactful therapies for underserved patient populations.



In conclusion, Immedica's acquisition of Marinus Pharmaceuticals is a strategic move that complements its global rare disease business, accelerates its growth into the North American market, and provides an immediate revenue-generating rare disease product and an experienced commercial team. The acquisition is expected to accelerate Immedica's revenue growth and expand its presence in the United States, marking a new chapter in its mission to deliver impactful therapies for underserved patient populations.